Auvelity Does Not Need to Be Tapered When Switching to Bupropion
When switching from Auvelity (dextromethorphan/bupropion) to bupropion monotherapy, tapering is not necessary because bupropion is already a component of Auvelity and patients are already tolerating the bupropion dose. You can directly transition to an equivalent or adjusted dose of bupropion without a taper period.
Rationale for Direct Switching
Auvelity contains 105 mg of bupropion hydrochloride (extended-release) plus 45 mg of dextromethorphan hydrobromide per tablet, dosed twice daily 1. This means patients on Auvelity are already receiving 210 mg/day of bupropion. The pharmacokinetics show that bupropion in Auvelity reaches steady state within 8 days with an elimination half-life of approximately 15 hours 1.
The key consideration is that you're only discontinuing the dextromethorphan component, not the bupropion. Since the patient is already on bupropion and tolerating it, there's no physiological reason to taper. The dextromethorphan component has a 22-hour half-life when combined with bupropion 1, but discontinuation of NMDA antagonists like dextromethorphan does not typically require tapering in the same way that antidepressants affecting serotonin do.
Practical Switching Strategy
Direct switch approach:
- Stop Auvelity (45 mg dextromethorphan/105 mg bupropion twice daily)
- Start bupropion 150 mg twice daily (300 mg/day total) the next day
- This provides a similar or slightly higher bupropion dose than what the patient was receiving in Auvelity
Dose considerations:
- If the patient was on Auvelity twice daily (210 mg bupropion total), switching to bupropion SR/XL 300 mg daily or 150 mg twice daily is appropriate
- Monitor for any changes in depressive symptoms since you're removing the dextromethorphan's NMDA antagonism and sigma-1 agonism 1
- The bupropion component alone may not provide the same antidepressant efficacy as the combination, as clinical trials showed superior efficacy of the combination versus bupropion monotherapy 2, 3
Important Caveats
Watch for symptom recurrence: The combination of dextromethorphan-bupropion showed significantly greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to bupropion alone, with effects seen as early as week 1-2 2, 3. Removing the dextromethorphan component may result in loss of therapeutic benefit, so close monitoring for depressive symptom return is essential.
Seizure risk remains: Bupropion lowers the seizure threshold regardless of whether it's in Auvelity or as monotherapy 4. Continue to avoid in patients with seizure disorders, brain metastases, or other seizure risk factors.
No withdrawal syndrome expected: Unlike SSRIs or SNRIs that commonly cause discontinuation syndromes requiring tapering 5, neither bupropion nor dextromethorphan typically produces significant withdrawal symptoms when stopped abruptly. The evidence for bupropion shows it can be stopped without tapering in most clinical scenarios 4.
Clinical Monitoring After Switch
- Assess depressive symptoms within 1-2 weeks post-switch
- Monitor for any neuropsychiatric changes (though these are uncommon) 4
- If depressive symptoms worsen, consider that the patient may have been responding specifically to the dextromethorphan component and may need an alternative strategy
The bottom line: Simply stop Auvelity and start bupropion at an equivalent dose the next day—no taper needed.